The effectiveness of major ozone autohemotherapy in the treatment of fibromyalgia syndrome

Major ozone autohemotherapy in the treatment of fibromyalgia



Fibromyalgia, Ozone, Hemotherapy, Oxidative stress, Pain


Background/Aim: Fibromyalgia syndrome (FMS) is a disease that seriously affects the quality of life. Although many modalities are used in treatment, there is still no common protocol. The aim of this study was to evaluate the effectiveness of major autohemotherapy (MAH) with ozone, which has come into use in recent years.

Methods: The retrospective cohort study included 45 male and female patients who were admitted to the Physical Medicine and Rehabilitation (PMR) outpatient clinic of Private Medar Hospital between January 2017 and October 2020 and were treated with MAH for a diagnosis of FMS. Evaluations were made before and after the last session of treatment using a visual analog scale (VAS), the Fibromyalgia Impact Questionnaire (FIQ) and the Short Form Health Survey-36 (SF-36). The scores of the patients were compared.

Results: Posttreatment VAS and FIQ scores decreased significantly (P = 0.014, P = 0.022 respectively) compared to pretreatment. After treatment, SF-36; PF, PH, EP, Fatigue, EW, SF, Pain, GH, HC scores increased significantly (P < 0.05 for all) compared to before treatment. The use of analgesics after treatment decreased significantly (P = 0.033) compared to before treatment.

Conclusion: MAH applied twice a week is an effective and practical method in the treatment of FMS.


Download data is not yet available.


Wolfe F, Clauw DJ, Fitzcharles MA, et al. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res. 2010;62:600–10. DOI:

Heidari F, Afshari M, Moosazadeh M. Prevalence of fibromyalgia in general population and patients, a systematic review and meta-analysis. Rheumatol Int. 2017 Sep;37(9):1527-39. DOI:

Clauw DJ (2014) Fibromyalgia: a clinical review. JAMA. 311(15):1547–55. DOI:

Fitzcharles MA, Ste-Marie PA, Goldenberg DL, Pereira JX, Abbey S, Choinière M, et al. 2012 Canadian Guidelines for the Diagnosis and Management of Fibromyalgia Syndrome. Erişim tarihi: 12.8.2017.

Sarzi-Puttini P, Atzeni F, Salaffi F, Cazzola M, Benucci M, Mease PJ. Multidisciplinary approach to fibromyalgia: what is the teaching? Best Pract Res Clin Rheumatol. 2011;25(2):311-9. DOI:

Bazzichi L, Giacomelli C, Consensi A, Giorgi V, Batticciotto A, Di Franco M, Sarzi-Puttini P. One year in review 2020: fibromyalgia. Clin Exp Rheumatol. 2020 Jan-Feb;38 Suppl 123(1):3-8.

Verga C. Nuovo approccio terapeutico alle ernie e protrusioni discali lombari. Rivista Di Neuroradiologia 1989;2:148. DOI:

Riva Sanseverino E. Knee joint disorders treated by oxigenozone therapy. Europa Medicophysica 1989;3:163-70.

Demirhan Dıraçoğlu. Ozone-oxygen therapies in musculoskeletal diseases Turk J Phys Med Rehab 2016;62(2):183-91. DOI:

Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, et al. The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum. 1990;33(2):160-72. DOI:

Price DD, McGrath PA, Rafii A, Buckingham B. The validation of visual analogue scales as ratio scale measures for chronic and experimental pain. Pain.1983;17(1):45–56. DOI:

Sarmer S, Ergin S, Yavuzer G. The validity and reliability of the Turkish version of the Fibromyalgia Impact Questionnaire. Rheumatology International 2000;20:9-12. DOI:

Angel Garcia D, Martinez Nicolas I, Saturno Hernandez PJ. Clinical approach to fibromyalgia: synthesis of evidencebased recommendations, a systematic review. Reumatologia Clinica. 2016;12:65–71. DOI:

Burckhardt CS, Clark SR, Bennett RM. The fibromyalgia impact questionnaire: development and validation. J Rheumatol. 1991;18(5):728–33.

Demiral Y, Ergor G, Unal B, et al. Normative data and discriminative properties of short form 36 (SF-36) in Turkish urban population. BMC Public Health. 2006;6:247. DOI:

Viebahn-Hänsler R, Lee A. The Use of Ozone in Medicine. Medicina Biologica; 2002.

Moreno-Fernández A, Macías-García L, Valverde-Moreno R, Ortiz T, Fernández-Rodríguez A, Moliní-Estrada A, De-Miguel M. Autohemotherapy with ozone as a possible effective treatment for Fibromyalgia. Acta Reumatol Port. 2019 Sep 29;44(3):244-9.

Tirelli U, Cirrito C, Pavanello M, Piasentin C, Lleshi A, Taibi R. Ozone therapy in 65 patients with fibromyalgia: an effective therapy. Eur Rev Med Pharmacol Sci. 2019 Feb;23(4):1786-8.

Tirelli U, Cirrito C, Pavanello M. Ozone therapy in 40 patients with fibromyalgia: an effective therapy. Ozone Therapy 2018;3:43-5. DOI:

Balestrero R, Franzini M, Valdenassi L. Use of oxygen-ozone therapy in the treatment of fibromyalgia. Ozone Therapy 2017;2:7-11. DOI:

Tuzcu A, Baykara RA, Alışık M, Omma A, Acet GK, Dogan E, Cure MC, Duygun F, Cure E, Erel O. Alteration of Thiol-Disulfide Homeostasis in Fibromyalgia Syndrome. Acta Medica (Hradec Kralove). 2019;62(1):12-8. DOI:

Smith NL, Wilson AL, Gandhi J, et al. Ozone therapy: an overview of pharmacodynamics, current research, and clinical utility. Med Gas Res. 2017;7:212-9. DOI:

Bocci V. Ozone as Janus: this controversial gas can be either toxic or medically useful. Mediators Inflamm 2004;13:3-11. DOI:

Alexander A, Baeza J, Vijail Sheel K, Ozone in Non-Rheumatic Locomotor System Pathologies. ISCO3 2014.

Geneen LJ, Moore RA, Clarke C, Martin D, Colvin LA, Smith BH. Physical activity and exercise for chronic pain in adults: an overview of Cochrane Reviews. Cochrane Database of Systematic Reviews 2017;4:CD011279. DOI:






Research Article

How to Cite

Ahi ED, Afsar SI. The effectiveness of major ozone autohemotherapy in the treatment of fibromyalgia syndrome: Major ozone autohemotherapy in the treatment of fibromyalgia. J Surg Med [Internet]. 2022 Aug. 31 [cited 2024 Apr. 19];6(8):746-50. Available from: